Emerging lymphatic imaging technologies for mouse and man

Eva M. Sevick-Muraca, Sunkuk Kwon, and John C. Rasmussen

The Center for Molecular Imaging, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA.

The lymphatic circulatory system has diverse functions in lipid absorption, fluid homeostasis, and immune surveillance and responds dynamically when presented with infection, inflammation, altered hemodynamics, and cancer. Visualization of these dynamic processes in human disease and animal models of disease is key to understanding the contributory role of the lymphatic circulatory system in disease and to devising effective therapeutic strategies. Longitudinal, non-destructive, and repeated imaging is necessary to expand our understanding of disease progression and regression in basic science and clinical investigations. Herein we summarize recent advances in in vivo lymphatic imaging employing magnetic resonance, computed tomography, lymphoscintigraphy, and emerging optical techniques with respect to their contributory roles in both basic science and clinical research investigations.

Introduction

Despite the diverse and dynamic roles that the lymphatic vasculature plays in healthy and pathological processes, there have historically been few methods to non-invasively image the response of lymphatics within in vivo animal models of human disease and even fewer methods suitable for clinical investigations. The interrogation of lymphatics in mice often requires visualization of blue dye–stained lymphatic vessels in dissected tissues or tissue sectioning for immunohistological staining of the lymphatic markers VEGFR-3, prospero-related homeobox 1 (PROX1), podoplanin, and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) in order to identify evidence of lymphangiogenesis, lymphatic vessel regression, or changes in function from single snapshots. This is in contrast to the blood vascular circulatory system, which is not only readily visualized in exposed tissues, but is routinely and non-invasively imaged using magnetic resonance (MR) and CT angiographic techniques that involve intravenous delivery of contrast agents. Unfortunately, locating and cannulating a lymphatic vessel can be significantly invasive for clinical research and nearly impossible in basic science investigations that utilize transgenic mouse models. While Doppler ultrasound for functional blood flow imaging depends upon scattering of moving red blood cells, the comparatively acellular lymph escapes interrogation using this technique. Molecular imaging approaches are under development for the diagnosis, stratification, selection, and assessment of molecular therapies in a variety of cardiovascular conditions, including apoptosis, tumor angiogenesis, thrombosis, atherosclerosis, and myocardial infarction (1). However, molecular targets of lymphangiogenesis and lymphatic vessel remodeling have not yet been fully developed, thereby limiting these technologies for basic science and clinical investigations.

The objective of this Review is to first summarize current and emerging in vivo imaging approaches that facilitate both basic science and clinical investigations of lymphatic vasculature, and secondly, to review how these imaging tools can contribute to our understanding of the role of the lymphatic circulation in health and disease first in animal models and then in humans. While there are several reviews on methods for preclinical or clinical lymphatic imaging (2–6), including LN mapping (LNM) (6, 7), herein we emphasize emerging optical imaging and fluorescent protein gene reporter technologies with sufficient in vivo temporal and spatial resolution to provide informative contributions in basic science and/or clinical research investigations of diseases in which the lymphatics are implicated.

Imaging lymphatic architecture in humans and mice

With the exception of clinical MRI of dilated lymphatics with stagnated lymph flow (8) and gene reporter imaging in transgenic animal studies (described below), all current and emerging non-invasive lymphatic imaging approaches require the administration of an exogenous contrast agent (Figure 1). High-resolution lymphangiography of the peripheral and truncal lymphatics requires the administration of exogenous x-ray or MR contrast agents either directly into the lymphatics via cannulation of a lymphatic vessel (direct lymphangiography; Figure 1, route ii) (9) or indirectly into the lymphatic plexus via intradermal injection (indirect or interstitial lymphangiography; Figure 1, route i) (10). Owing to the difficulties of cannulating small lymphatics in mouse models, direct lymphangiography is not employed in basic science investigations. Instead, indirect MR lymphangiography is used, in which gadolinium-based contrast media is injected into the intradermal and subcutaneous spaces that drain into the dermal capillary plexus. The lymphatic capillary plexus within these spaces contains initial lymphatics that have a discontinuous basement membrane and, under normal circumstances, actively take up particle- or fluid-based contrast agents for transport to peripheral and truncal lymphatics before emptying into the blood circulation. Because of the confined space of the capillary plexus, contrast volumes are limited to microliters in animals and to approximately 0.1 ml in humans, although larger volumes of 1 to 5 ml have been injected into the subcutaneous space for slower uptake into the lymphatics. Indirect MR lymphangiography in the legs of lymphedema patients (11–13) has excellent resolution and better visualization than lymphoscintigraphy (14) (Figure 2, A and B), but this technique has not been used for non-invasive imaging of truncal lymphatics, as has been demonstrated with x-ray direct lymphangiography.
With advances in MR contrast agent development, indirect MR lymphangiography has enabled the localization of LNs and peripheral lymph drainage pathways in animals (15–18). Albumin-binding gadolinium-based agent gadofoveset, recently FDA-approved for use in hemovascular applications, might also potentially be employed off-label for interstitial, indirect MR lymphangiography (14).

Lymphoscintigraphy (reviewed in refs. 19–21) provides a routine clinical means to assess lymphatic function and architecture in humans, albeit with low spatial and temporal resolution, and is not typically used in investigations employing mouse models of human disease. The technique involves the intradermal administration of a radiocolloid that is taken up by the lymphatics and, typically after hours, imaged using a gamma camera for tens of minutes in order to obtain a grainy image of the lymphatics (see Figure 2B). Lymphatic function can be assessed either by measuring the time between the injection in distant digits and the appearance of tracer in major lymphatic basins, such as the inguinal or axillary LN basins (22), or by monitoring the depot clearance of an intradermally injected agent (23).

Fluorescence microlymphangiography (FML) represents the first fluorescence technique used to non-invasively interrogate the lymphatics in mice or in humans with high resolution. FML employs the intradermal administration of a fluorescent dye, FITC conjugated to dextran (FITC-dextran), and video fluorescence microscopy techniques to collect high-resolution images. Owing to the limited penetration depth of light at visible wavelengths and tissue scattering, only the initial capillaries within the first 100 to 150 microns of tissue depth can be visualized in humans. In preclinical investigations, the honeycomb-like lymphatic structure in rat and mouse tails can be non-invasively imaged (24, 25). In normal control subjects, FML enables visualization of only a few of the initial lymphatics close to the intradermal depot of FITC dye, while in subjects with lymphedema, the visualized network of initial lymphatics surrounding the injection sites is considerably larger, presumably due to higher pressures in proximal conducting lymphatic vessels that prevent efflux of dye from the initial capillaries into conducting and collecting lymphatic vessels (Figure 2C). The administered fluorescent dye can also penetrate deeper into collecting and conducting lymphatic vessels, where it escapes optical interrogation by microscopy techniques and, in subjects with congenital and acquired lymphedema, can be seen to reappear at tissue surfaces distant to the injection site, due again to higher pressures or blockage in proximal conducting vessels that redirect lymph flow distally as well as into the initial capillary vessels (26–29). Tissue penetration of FML techniques can be enhanced using indocyanine green (ICG), a dye that is approved in humans for intravenous administration, has been used in hepatic
and cardiovascular testing and retinal angiography, and can be excited by tissue-penetrating near-infrared (NIR) light (>780 nm). While poorly fluorescent, the dye may be used in humans in an off-label, intradermal route of administration for interrogation of the lymphatics. Confocal fluorescence microscopy techniques employing ICG focus on pre-surgical and intraoperative sentinel lymph node microsurgery in a case of lower extremity lymphedema (43). Because lymphatic vessel reconstitution plays an important role in transplantation, NIRF imaging of the lymphatics with ICG has also been used to assess tissue rejection in an animal model of hind limb transplantation (44), suggesting potential uses in clinical regenerative medicine. Nonetheless, tissue penetration that depends upon the imaging performance of individual camera systems is a limitation, and NIRF imaging cannot be used to visualize the truncal lymphatics in adults and children as can x-ray lymphangiography employing intra-lymphatic contrast agents. Thus, non-invasive NIRF imaging of ICG has been confined to imaging the peripheral lymphatics (including initial, collecting, and conducting) in both humans and animals.

**Imaging techniques to assess lymphatic function**

Unlike other lymphatic imaging approaches described in Table 1, NIRF lymphatic images can be collected rapidly with millisecond acquisitions (33), allowing for the non-invasive interrogation of function in collecting and conducting lymphatic vessels (40, 45, 46) and the quantitative assessment of the lymph pump frequency and apparent velocity in the collecting and conducting lymphatics of both mice and humans (Supplemental Videos 1 and 2; supplemental material available online with this article; doi:10.1172/JCI71612DS1). The mechanism for lymph pumping, an intrinsic property of the lymphatic muscle, is due in part to the rhythmic constriction/relaxation cycle of vascular smooth muscle cells, called lymphangions, that are bounded by valve leaflets that open and close in an orchestrated manner to mediate unidirectional, efficient lymph flow (reviewed in ref. 47). The lymph pump is thought be controlled by the autonomic nervous system and is critical to tissue fluid homeostasis and immune cell transport. The identification of factors that affect lymphatic pumping is an active area of research that will contribute to the development of...
Table 1
Summary of imaging modalities for visualizing the lymphatic vasculature in vivo within small and large animals and humans

<table>
<thead>
<tr>
<th>Modality</th>
<th>Temporal resolution (acquisition times)</th>
<th>Spatial resolution</th>
<th>Depth resolution</th>
<th>Small animals</th>
<th>Large animals</th>
<th>Humans</th>
<th>Contrast agents</th>
<th>Comments and selected references</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-ray lymphangiography, direct</td>
<td>ms/exposure; requires surgical intervention to cannulate lymphatic vessel</td>
<td>&lt;1 mm</td>
<td>Whole body</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Oily, iodinated agents such as Ethiodol/Lipiodol</td>
<td>Used on a limited basis due to incidence of clinical complications and technical skill required to locate and cannulate lymphatic vessel (9, 112, 113)</td>
</tr>
<tr>
<td>X-ray lymphangiography, indirect</td>
<td>ms/exposure</td>
<td>&lt;1 mm</td>
<td>Whole body</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Water-soluble iodinated agents such as Iotasul</td>
<td></td>
</tr>
<tr>
<td>X-ray computed tomography</td>
<td>&gt;20 s/exposure, dependent on region of interest and desired resolution</td>
<td>1–3 mm</td>
<td>Whole body</td>
<td>Limited</td>
<td>Yes</td>
<td>Yes</td>
<td>Water-soluble iodinated agents such as Iopamidal</td>
<td>Visualizes LNs and some larger lymphatic vessels (115, 116)</td>
</tr>
<tr>
<td>MRI lymphangiography</td>
<td>&gt;2 min/exposure, dependent on region of interest and desired resolution</td>
<td>0.1–0.3 mm in mice, 1 mm in human</td>
<td>Whole body</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Gadolinium or iron oxide–based agents; dendrimer-based macromolecules</td>
<td>Difficult to resolve healthy, intact lymphatic vessels (16, 117–119)</td>
</tr>
<tr>
<td>MRI (non-contrast)</td>
<td>Minutes/exposure</td>
<td>1 mm</td>
<td>Whole body</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Unknown</td>
<td>Can only resolve dilated lymphatics filled with stagnant lymph (8)</td>
</tr>
<tr>
<td>Lymphoscintigraphy</td>
<td>20–60 min/exposure</td>
<td>~1 cm</td>
<td>Whole body</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Radiolabeled sulfur colloid, radiolabeled dextran; technitium most commonly used isotope</td>
<td>Visualizes large lymphatic vessels and nodes only (20, 23)</td>
</tr>
<tr>
<td>FML</td>
<td>Video rates</td>
<td>50 μm</td>
<td>200 μm</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>FITC-dextran</td>
<td>Visualizes the initial lymphatics near the injection site (25–29)</td>
</tr>
<tr>
<td>NIRF</td>
<td>Typically 50–800 ms/image</td>
<td>~200 μm at tissue surface; due to photon scatter, resolution decreases as depth increases, but larger, deeper vessels are visualized</td>
<td>Varies with vessel diameter; larger nodes can be visualized up to 3–4 cm deep</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>NIRF dyes, Qdots, gene reporters</td>
<td>Initial lymphatics as well as collecting and conducting vessels observed; active lymphatic propulsion observed in small and large animals as well as in humans; photon scattering limits spatial resolution; only off-label use of ICG is currently allowed in humans (31, 35, 37)</td>
</tr>
</tbody>
</table>
new pharmacologic strategies to correct lymphatic insufficiency. Lymphatic dysfunction is generally diagnosed based upon onset of late-stage, irresolvable symptoms of edema, chyloous ascites, and chylorrhoea. Early detection of dysfunctional lymphatic transport in asymptomatic patients before onset of symptoms could enable earlier diagnoses and more effective treatments. Indeed, in the specific case of breast cancer-related lymphedema, Gergich and coworkers (48) found that early intervention could improve the outcome of upper extremity lymphedema. Clinical decisions in other conditions/diseases in the areas of wound care, diabetes, cancer care, and peripheral vascular disease might also be improved if the contributory role of the lymphatic function were evaluated through non-invasive imaging techniques.

Because of its high temporal resolution, NIRF imaging has been used to image the lymphatic function and architecture in patients with metastatic cancer (49) and in mouse models of metastasis (39, 50–52). In humans, NIRF lymphatic imaging has been used to show that manual lymphatic drainage therapy directly affects lymphatic pumping in normal healthy adults and in some subjects with early lymphedema (53), thus providing direct evidence of benefit needed by the U.S. Centers for Medicare and Medicaid for continuing coverage of lymphedema treatments (54). The changes in lymph pumping have been non-invasively imaged in preclinical animal models (55) of salt-induced hypertension (56), rheumatoid arthritis (57, 58), acute inflammation (59), and wound healing (60). Furthermore, cytokine-induced changes in lymph pumping, including retrograde lymph flow, have been non-invasively visualized and quantified (59) with results that are consistent with invasive, intravital fluorescence measurements using FITC-dextran (61). Because tissue optical properties limit the utility of visibly excited fluorescent dyes in non-invasive imaging, dyes that can be excited by NIR light offer the most straightforward means to understand which factors affect lymphatic pumping in non-invasive mouse and in human investigations.

**Imaging mesenteric and truncal lymphatics**

In contrast to the peripheral lymphatics, the mesenteric lymphatics are a major route for dietary lipid uptake and transport, but little is known about the precise mechanisms mediating lipid transport and metabolism. Lipids are absorbed as monoglycerides and fatty acids from the intestinal lumen into the enterocytes, where they are esterified into triglycerides and packaged to form chylomicrons (62, 63). The chylomicrons are too large to enter the blood capillaries and must be taken up by the lacteal lymphatics (Figure 1, route iii), then transported through the lymphatic system to the thoracic duct, where they enter the bloodstream via the subclavian vein. Non-invasive, direct imaging of the mesenteric lymphatic system is not currently possible in animals or humans due to its inaccessible, anatomic location and lack of an imaging agent that is readily taken up by the lacteals. Mesenteric lymphatic vessels in mice and rats have been imaged in situ using intravital optical microscopy after mesenteric loops were exteriorized (47). Fluorescent lipid analogs provide a way to invasively image mesenteric lymphatics and lipid metabolism. A fluorescently labeled 16-carbon-chain fatty acid, 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (BODIPY FL C16), has been used as a lipid tracer to invasively study lymphatic architecture and function in the mesentery lymphatics (Figure 3, A–C, and ref. 64). After oral gavage, BODIPY FL C16 is taken up by the lacteals and transported through the thoracic duct, where they enter the bloodstream via the subclavian vein. Non-invasive, direct imaging of the mesenteric lymphatic system is not currently possible in animals or humans due to its inaccessible, anatomic location and lack of an imaging agent that is readily taken up by the lacteals. Mesenteric lymphatic vessels in mice and rats have been imaged in situ using intravital optical microscopy after mesenteric loops were exteriorized (47).

**Figure 3** Images of the mesenteric lymphatics, truncal lymphatics, and thoracic duct. (A–C) In situ imaging of mesenteric lymphatics (dashed arrow) in exteriorized mesentery (A) and exposed thoracic duct of mouse following oral gavage of BODIPY FL C16 in normal (B) and Chy (C) mice. Note the leaky thoracic duct in the Chy mouse. (D) Mesenteric mouse lymphatics visualized following oral gavage of heavy cream. (E) Expanded view of the area within the dashed box in D. (F) The exposed thoracic duct can also be imaged, although not as clearly, following intradermal administration of ICG in the hind limb. Scale bar: 1 cm.
mice, the thoracic duct has been visualized intraoperatively using fluorescence imaging following administration of ICG in the hind limbs (Figure 3F and ref. 72), but tissue penetration issues prevent the non-invasive visualization of the thoracic duct in adult human subjects and currently limit non-invasive visualization in infants and animal models.

Emerging imaging agents for the lymphatics
FITC and ICG are the only visible and NIR excited fluorescent lymphatic agents used in human studies, but new fluorescent imaging agents have emerged for preclinical investigations and may be transflectable to humans in the future. Fluorescent contrast agents that are brighter and may be more suitable for non-invasive imaging include quantum dots (Qdots) (73) and a NIRF-labeled, albumin-binding domain peptide that measures protein uptake and lymphatic transport (74). Molecular imaging agents that target the lymphatic vasculature are also in development. Using phage screening, Laakkonen et al. identified and fluorescently labeled a cyclic 9-amino-acid peptide, LyP1, which homes to lymphatic endothelial cells (LECs) and tumor cells (75). LYVE1 is a major receptor for ECM glycosaminoglycan hyaluronan on LECs (76) and has been fluorescently labeled with NIRF dye to show staining of lymphatic vessels in swine (45). Fluorescently labeling (77), radiolabeling (78), or conjugating magnetic nanoparticles (79) to a LYVE1 antibody has allowed investigators to visualize lymphatics through fluorescence, PET, and molecular MRI. Fluorescently labeled antibodies targeting CD11b and GR1 have allowed for imaging of immune cell migration within lymphatic vessels using intravital fluorescence imaging (58). Dendritic cell trafficking to LNs has been performed using non-invasive MRI techniques with ultra-small iron oxide particles (USPIOs) that are administered intradermally (80).

Gene reporters for lymphatic imaging in transgenic mouse models of human disease
Gene reporter imaging used in transgenic mouse models of human disease involves the use of fluorescent or bioluminescent reporters for visualizing lymphatic vessels, usually with intravital imaging techniques. Expressed under the control of the LEC gene marker Prox1, the fluorescent proteins GFP (81), mOrange (82), and mTomato (83) have been used in transgenic animals to visualize lymphatic vessels with intravital microscopy. The role of NO in lymphatic contractile activity and immune responses was probed using mice that express the fluorescent protein DsRed under the control of a smooth muscle cell promoter (Acta2) (61). More recently, animals have been developed to express the dual reporter, EGFP-LUC, consisting of EGFP and luminescent LUC reporters under the control of Vegfr3. In this model, high-resolution intravital fluorescence imaging is used to collect fluorescence from EGFP at the study endpoint, while lower-resolution, non-invasive bioluminescence imaging is used to longitudinally assess lymphatic vessels in vivo during development, wound healing, inflammation, and tumor metastasis (84). The dual reporter approach marries imaging information from high-resolution intravital microscopy at the endpoint of the animal study, with low-resolution, non-invasive...
bioluminescence to longitudinally assess lymphatic remodeling responses. In contrast to the visibly excited fluorescent gene reporters, newer, far-red-shifted fluorescent gene reporters (85, 86) can be imaged non-invasively and longitudinally in whole animals (our unpublished observations and ref. 87), suggesting they may extend fluorescent gene reporter imaging beyond intravital imaging and facilitate non-invasive, longitudinal imaging of lymphatic remodeling. To date, these far-red fluorescent gene reporters have not been employed in any transgenic animal models, but could dramatically affect future preclinical study of the lymphatics.

**Phenotyping human lymphatic disorders in mice and man**

Table 1 is a summary of the non-invasive imaging techniques used both in mice and humans. The ability to directly relate lymphatic phenotypes between human subjects and transgenic animal models of lymphatic disorders is an important advantage unique to fluorescence imaging, particularly NIRF and FML. For example, using NIRF imaging, the abnormal, hyperplastic lymphatic phenotype associated with an inducible knockout of Rasa1 in a transgenic mouse model (88) was recently associated with that of a human subject with the rare syndromic disorder of capillary malformation–arteriovenous malformation, which is caused by an inactivating mutation in RASAI (Figure 4, A and B). The patient exhibited unusually dilated lymphatics in the unaffected lower extremity compared with normal subjects (Supplemental Videos 2 and 3) (89). Abnormal phenotypes of defective drainage patterns, hypoplasia, and retrograde lymph flow have also been imaged in Prowad heterozygous mice (38) and in Chy mice with a loss-of-function Vegfr3 mutation (90) using NIRF lymphatic imaging. In the latter, NIRF imaging of the hyperplastic lymphatic phenotype in the Chy mouse and a subject with a Vegfr3 mutation are strikingly similar (Figure 4, C–F). FML also confirms the lack of initial lymphatics in Milroy’s disease, which is associated with Vegfr3 mutations (91). The Chy model also provides an animal model for developing new pharmacologic strategies to stimulate lymphatic vessel development in human lymphedema (92). In a preclinical study, Tammela and coworkers (93) used FITC-dextran imaging to demonstrate enhanced regrowth of lymphatic vessels and improved lymphatic function across sites of LN dissection following Vegfc/D gene therapy. Thus, fluorescence lymphatic imaging can provide a preclinical method for directly assessing emerging molecular therapeutics on the initial, conducting, and collecting peripheral lymphatics (51).

**Lymphatic imaging for cancer diagnostics and therapeutic development**

Recent research has focused on the development of new imaging methods for SLNM in cancer patients to augment lymphoscintigraphy, thereby improving staging by imaging only cancer-positive LNs, and to assess tumor-associated lymphangiogenesis. SLNM is currently conducted clinically with lymphoscintigraphy and blue dye, the latter of which is visually apparent intraoperatively, to identify tumor-draining LNs for subsequent biopsy. Clinical approaches proposed for improved SLNM include intraoperative use of ICG (94) and a recently approved, macrophage-targeted, radiolabeled sugar (tilmanocept) (95, 96) that has also been labeled with a NIRF dye (97) or a radionuclide/NIRF conjugate (98). Other investigational approaches for SLNM conducted in preclinical studies have employed QDots (99), MR lymphangiography with Gadolinium-based contrast agents (100), and gold nanorods that were tracked using photoacoustic imaging (101).

While the lacteals of the mesenteric lymphatics and the initial lymphatics of the peripheral circulation provide the physiologic points of entry into the lymphatic vasculature, intravenously administered contrast agents can enter into the lymphatics via the highendothelial venules of LNs (Figure 1, route iv), as well as through the reticuloendothelial system. For example, when USPIOs, used as contrast agents in MRI, are administered intravenously, either they gain access to the interstitium, are taken up by the lymphatics and transit to LNs or are captured by mononuclear phagocytic cells that then home to LNs (reviewed in ref. 102). Upon accumulation of the USPIOs in draining LNs, a reduced signal intensity on T2/T2* weighted images creates negative contrast of draining LNs, allowing non-invasive detection. However, when metastases block drainage, the LN appears bright on the T2/T2* MRI, enabling potential differential identification of cancer-positive over cancer-negative LNs (103). Gadofosves triosodium (reviewed in ref. 104) has also recently been employed as a MR-positive T1 contrast agent for axillary LNs after intravenous administration (105).
The ability to non-invasively image cancer-positive LNs could obviate the need for LN dissection for the purposes of cancer staging. Molecularly specific imaging for detection of cancer-positive LNs has been proposed, employing intravenous administration of radiolabeled and fluorescently labeled antibodies for targeting cancer cells (106, 107). These antibody-based approaches possess high specificity to the cancer-specific antigen, but also typically contain the Fc domain to which immune cells resident within LNs can bind (108). As a result, molecular imaging approaches that employ a full antibody as opposed to antibody fragments or Fc-silenced antibodies are likely to suffer from false positives and reduced specificity. To date, there remains no viable means to accurately detect cancer-positive LNs with a targeted molecular imaging agent.

The use of imaging to assess the interaction between metastasizing cancer cells and the host lymphatic vasculature represents a critical cancer research tool. Longitudinal imaging of functional and architectural lymphatic changes in patients (49) and in animal models of cancer provides a window for assessing the role of the lymphatics in cancer progression and metastasis (39, 51, 52). Preclinical imaging studies to track the migration of cancer cells marked with a fluorescent gene reporter have been pioneered by a number of investigators (77, 109). For example, the leaky and tortuous tumor lymphatic vessel phenotype around a tumor less than 2 mm in diameter can be readily imaged (Figure 5, A and B) using the far red fluorescent protein, iRFP, which is stably expressed by a human inflammatory breast cancer (IBC) cell line and ICG lymphatic imaging (110). IBC is rare in humans but is known to infiltrate the skin and lymphatic vessels of the breast, thus partially obstructing subdermal lymphatics and causing breast lymphedema. Figure 5, C and D, provides an example of NIRF lymphatic imaging of women diagnosed with IBC and invasive ductal carcinoma with observed abnormal lymphatic drainage suggesting lymphatic reorganization of the dermal lymphatics (111).

Conclusions

The armamentarium of lymphatic imaging techniques for clinical research investigations and longitudinal imaging in animal models of human disease has accelerated biological discoveries and may hasten their clinical translation. In less than a decade, significant advances in NIRF lymphatic imaging, nanotechnology-based MRI agents, and gene reporter technologies have provided new tools for interrogating the diverse functions of the lymphatic vasculature. For example, lymphatic imaging may be useful in determining the impact of specific signaling pathways when used in conjunction with transgenic animal models of human disease and enable visualization of the effects of therapeutic interventions. The development of transgenic models using far-red fluorescent gene reporters could contribute to lymphatic research by enabling non-invasive imaging of dynamic lymphatic processes and pathologies. Because of the inherent plasticity of the lymphatic system, longitudinal imaging techniques both for preclinical and clinical investigations need to be further developed, particularly for mesenteric and truncal lymphatics. While not all lymphatic imaging modalities are amenable to both clinical and preclinical investigation, their strategic combination provides opportunities for biological discovery and clinical translation in lymphatic research. The clinical application of lymphatic imaging techniques in cancer care, cancer survivorship, chronic wounds, peripheral vascular disease, and other conditions in which the lymphatics potentially mediate clinical outcomes may enable more efficient diagnoses and better treatments.

Acknowledgments

This work was supported in parts by NIH grants R01 HL092923 (to E.M. Sevick-Muraca), R01 CA128919 (to E.M. Sevick-Muraca), and R21 CA159293 (to S. Kwon). The authors acknowledge the assistance of Jessica Nollkamper in the preparation of the manuscript.

Address correspondence to: Eva M. Sevick-Muraca, Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, 1825 Pressler Street, SRB 330A, Houston, Texas 77030, USA. Phone: 713.500.3560; Fax: 713.500.3561; E-mail: eva.sevick@uth.tmc.edu.
review series


